STAAR Surgical Company PT Raised to $21.00 (STAA)
Equities researchers at Canaccord Genuity upped their price objective on shares of STAAR Surgical Company (NASDAQ:STAA) from $20.00 to $21.00 in a research report issued on Tuesday, Analyst RN reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price objective would indicate a potential upside of 11.82% from the stock’s previous close.
STAAR Surgical Company (NASDAQ:STAA) traded up 1.12% on Tuesday, hitting $18.99. The stock had a trading volume of 455,086 shares. STAAR Surgical Company has a 52-week low of $6.45 and a 52-week high of $19.74. The stock has a 50-day moving average of $17.56 and a 200-day moving average of $15.28. The company has a market cap of $721.0 million and a price-to-earnings ratio of 1878.00.
STAAR Surgical Company (NASDAQ:STAA) last issued its quarterly earnings data on Monday, April 28th. The company reported $0.04 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.01 by $0.03. The company had revenue of $20.20 million for the quarter, compared to the consensus estimate of $19.44 million. During the same quarter in the prior year, the company posted $0.08 earnings per share. The company’s quarterly revenue was up 12.1% on a year-over-year basis. On average, analysts predict that STAAR Surgical Company will post $0.17 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on STAA. Analysts at William Blair upgraded shares of STAAR Surgical Company from a “market perform” rating to an “outperform” rating in a research note on Monday, March 24th. Analysts at Benchmark Co. raised their price target on shares of STAAR Surgical Company from $15.00 to $21.00 in a research note on Monday, March 17th. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $17.83.
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye. The Company is the maker of lenses used worldwide in corrective or refractive surgery.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.